Born from the dream of breaking down barriers to equal access to healthcare
Located in the heart of Paris and born from a passion for synthetic biology, En Carta deploys its revolutionary technology through a powerful and versatile diagnostic platform.
We design accurate, accessible and affordable molecular diagnostics that can be used by anyone, anywhere in the world.
We are a diagnostic
solution for the future
We believe that democratizing access to simple solutions to detect and identify infections directly from home will revolutionize the patient journey.
We provide our customers with the full power of our molecular diagnostic platform:
Ready-to-use tests for validated targets.
The internal development of new tools capable of targeting virtually any DNA or RNA.
Our values
Integrity
Our diagnostics are used for medical applications.
We don't compromise on quality.
Based on the
evidence
Synthetic biology is a new and exciting science. The possibilities are endless, but we need a compass to help us choose what we can do.
Sustainability
We believe that following environmental, social and governance (ESG) best practices today will make En Carta a sustainable company.
En Carta technology powers the first and only portable molecular diagnostic devices, delivering PCR-equivalent accuracy without the need for an external power source
Our founding publications
En Carta closes €1.5 million funding round for Lyme disease diagnosis
En Carta Diagnostics has closed a €1.5 million funding round, led by Centrale Supélec Venture. This fundraising will enable En Carta to continue developing its diagnostic kit platform for Lyme disease.
May 22, 2024
En Carta presents its vision at the 50 Partners Day
Our CEO Guillaume Horreard and our CTO Margot Karlikow shared En Carta's mission on stage at the 50 Partner Day in front of other entrepreneurs and investors.
How will we transform the face of diagnostics? Find out in just 4 minutes!
Discover
March 7, 2024
En Carta Co-Founders Receive Prestigious DARPA Grant
Our co-founders Alex Green and Keith Pardee have secured a prestigious $17.7 million DARPA collaboration agreement for the SPITFIRE project.
Learn more
November 8, 2023
November 8, 2023
ASU Skysong Innovation Startup Challenge
Our technology convinced the jury, who awarded En Carta a prize of USD 25,000.
Learn more
March 7, 2024
CDL graduates
En Carta is a graduate of the Creative Destruction Lab incubator.
Learn more
May 22, 2024
50 Health Partners
Our CEO Guillaume Horréard presented En Carta Diagnostics at the 50 Partners annual conference, 50 Days.
Learn more
May 22, 2024
WILCO Graduates
En Carta Diagnostics has been selected to be part of the WILCO innovation accelerator for the S2022 biotech and smart pharma cohort.
En savoir plus
November 8, 2023
Nos laboratoires partenaires sont dans les nouvelles
En Carta relies on technologies from the best synthetic biology laboratories in the world.
You can learn more about them here:
https://www.alexgreenlab.org/news/
Learn more
March 7, 2024
Zika virus field clinical trials in the press!
The pioneering Zika virus study featuring our proprietary technology and led by our CTO Margot Karlikow was featured in several media outlets, including the MyScience portal and the University of Toronto press release.
Learn more
